| Literature DB >> 35970974 |
Ying Xia1, Cao Chen2,3, Jia Chen1, Chao Hu1, Wei Yang1, Lin Wang1,4, Lian Liu1, Li-Ping Gao1, Yue-Zhang Wu1, Dong-Dong Chen1, Qi Shi1,5, Zhi-Bao Chen6, Xiao-Ping Dong7,8,9,10.
Abstract
Activation and proliferation of microglia are one of the hallmarks of prion disease and is usually accompanied by increased levels of various cytokines and chemokines. Our previous study demonstrated that the level of brain macrophage colony-stimulating factor (M-CSF) was abnormally elevated during prion infection, but its association with PrPSc is not completely clear. In this study, colocalization of the increased M-CSF with accumulated PrPSc was observed by IHC with serial brain sections. Reliable molecular interaction between total PrP and M-CSF was observed in the brain of 263 K-infected hamsters and in cultured prion-infected cell line. Immunofluorescent assays showed that morphological colocalization of M-CSF with neurons and microglia, but not with astrocytes in brains of scrapie-infected animals. The transcriptional and expressing levels of CSF1R were also significantly increased in prion-infected cell line and mice, and colocalization of CSF1R with neurons and microglia was observed in the brains of prion-infected mouse models. Removal of PrPSc replication by resveratrol in SMB-S15 cells induced limited reductions of cellular levels of M-CSF and CSF1R. In addition, we found that the level of IL-34, another ligand of CSF1R, did not change significantly after prion infection, but its distribution on the cell types in the brains shifted from neurons in healthy mice to the proliferated astrocytes and microglia in scrapie-infected mice. Our data demonstrate activation of M-CSF/IL-34/CSF1R signaling in the microenvironment of prion infection, strongly indicating its vital role in the pathophysiology of prions. It provides solid scientific evidence for the therapeutic potential of inhibiting M-CSF/CSF1R signaling in prion diseases.Entities:
Keywords: CSF1R; IL-34; M-CSF; Microglia; Prion infection
Mesh:
Substances:
Year: 2022 PMID: 35970974 DOI: 10.1007/s12035-022-02989-y
Source DB: PubMed Journal: Mol Neurobiol ISSN: 0893-7648 Impact factor: 5.682